Q2 FY2026 · ended Jun 30, 2026 · Revenue $18.94M, +56.7% YoY · Filed Aug 5, 2026
Carlsmed, Inc. (CARL) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $18.9 million and a net loss of $10.5 million. Free cash flow was -$7.5 million. As of Jun 30, 2026 it held $70.2 million in cash and investments and $21.9 million in total debt.
Revenue
$18.94M
+56.7% vs year-ago quarter
Net income
$-10.51M
-55.3% vs year-ago quarter
Operating cash flow
$-7.36M
+51.6% vs year-ago quarter
Free cash flow
$-7.48M
+52.1% vs year-ago quarter
EPS
$-0.39
+73.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
27.30M
+2.7% vs year-ago quarter
Net cash
$48.33M
Q2 FY2026
Operating margin
-61.1%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CARL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carlsbad, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1794546
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $18.9M | $16.1M | $15.2M | $13.1M | $12.1M |
| Operating income | -$11.0M | -$9.3M | -$9.3M | -$9.0M | -$6.5M |
| Net income | -$10.5M | -$8.7M | -$8.6M | -$8.5M | -$6.8M |
| Diluted EPS | -$0.39 | -$0.32 | -$0.32 | -$0.40 | -$1.47 |
| Operating cash flow | -$7.4M | -$13.0M | -$5.3M | -$8.5M | -$15.2M |
| Free cash flow | -$7.5M | -$13.1M | -$5.4M | -$8.6M | -$15.6M |
| Total assets | $118.2M | $118.8M | $130.1M | $134.9M | $53.3M |
| Total liabilities | $34.0M | $26.5M | $31.3M | $28.2M | $27.6M |
| Stockholders' equity | $84.2M | $92.2M | $98.9M | $106.7M | -$83.1M |
| Cash and investments | $70.2M | $97.0M | $109.8M | $115.4M | $33.5M |
| Total debt | $21.9M | $17.3M | $17.4M | $17.6M | $17.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 30, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 8, 2026 | Sep 4, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2026 | Jun 3, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
All 97 Carlsmed, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.